Inhibiting "anchor" molecule in stem cells may improve marrow transplant process

Share this article:

The safety and efficiency of bone marrow transplants may improve due to the discovery of a rare molecule that establishes blood stem cells in their niche within the bone marrow.

The molecule—Robo4—is found only in the hematopoietic stem cells and in the endothelial cells of blood vessels. According to the new study findings, published in Cell Stem Cell (2011;8:72-83), hematopoietic stem cells—the key components in bone marrow transplants—use Robo4 to anchor themselves in the bone marrow where they reside.

In an increasingly common alternative to traditional bone marrow transplants, repeated drug injections are administered to usher stem cells away from bone marrow and into the bloodstream, from which they can be harvested and eventually groomed into different types of cells. The Robo4 discovery, however, creates an opportunity to find agents that can block the molecule in a safer and more effective fashion.

“If we can get specific and efficient inhibition of Robo4, we might be able to mobilize the hematopoietic stem cells to the blood more efficiently,” explained E. Camilla Forsberg, an assistant professor of biomolecular engineering at University of California–Santa Cruz, in a statement describing her team's work.

 

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Y-90 radioembolization: A new treatment for hepatic metastases from breast cancer

Yttrium-90 radioembolization is a minimally invasive treatment that may slow disease progression in breast cancer that has metastasized to the liver.

More sensitive testing may better define prognosis and treatment for leukemia

Nearly half of patients with the most common form of adult leukemia may have a distinct pattern of genetic abnormalities that could better define their prognosis and treatment.

Doxorubicin-ifosfamide combo improves progression-free survival in soft-tissue sarcoma

A new European study does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma.